Previously we have described the role of two 14mer peptides in autoimmune uveitis, PDSAg from the retinal autoantigen S-antigen (S-Ag) and B27PD from the sequence of disease-associated HLA-B molecules, which show antigenic mimicry. The retinal peptide gave rise to severe uveitis in the Lewis rat model of experimental autoimmune uveitis (EAU) and was effective in inducing oral tolerance, while the HLA peptide B27PD caused only mild disease, but it was at least equally effective in preventing uveitis by oral tolerance. Here, we further de®ned the major T cell epitopes on both peptides responsible for the different functions. For this purpose we tested C-and N-terminal truncations, and chimeras consisting of amino acid sequences of both peptides in vitro and in vivo. We were able to determine the motif for binding to Lewis rat MHC class II as well as those amino acids important for recognition by T cells speci®c for the retinal peptide. The minimal MHC-binding nonamer peptide of PDSAg was not recognized by TCR, and we also found striking differences of T cell recognition in vitro and in vivo. The ability to induce oral tolerance was not closely correlated with uveitogenicity or with strong binding to MHC class II molecules. Our data furthermore demonstrate the importance of speci®c and exact trimming of peptides to be presented on MHC class II, suggesting that the presentation of cryptic epitopes is favored or prevented by existence of multiple MHC-binding motifs within a certain amino acid sequence, which can result in different or altered T cell reactions.
Introduction
Antigenic mimicry is one of the mechanisms to explain the induction of immune responses to self-antigens that result in autoimmunity. In such a model, viral peptides mimicking tissue-speci®c autoantigens might play a role in diabetes (1), multiple sclerosis (2) and other autoimmune diseases (3) . Mimicry of bacterial and disease-associated HLA molecules was also proposed (4, 5) . Only few amino acid homologies or structural similarities are required for cross-reactivity (6, 7) between peptides in the case of T cell-mediated autoimmune diseases.
For autoimmune uveitis, an in¯ammatory disease of the eye, we have described mimicry of a peptide from the ocular autoantigen S-Ag (PDSAg, amino acids 341±354) and a peptide derived from the sequence of disease-associated HLA-B molecules (B27PD, amino acids 125±138) (8) . The pathogenic cells in uveitis are CD4 + /abTCR + and MHC class II-restricted T cells; however, statistical associations with HLA class I molecules [B27 (9,10), B51 (11) ] are well known. In our model, the HLA class I molecule serves as an autoantigen itself, being presented as a peptide on HLA class II and mimicking the retinal peptide. This offers an explanation for the role of HLA class I in human uveitis.
Lewis rats develop uveitis after immunization with the HLA peptide, although the conventional autoantigens for experimental uveitis in rats are retinal proteins such as S-Ag (12) , interphotoreceptor retinoid-binding protein (IRBP) (13) or peptides thereof. Molecular mimicry of S-Ag-and HLAderived peptide was demonstrated for pathogenic T cells and for gd T cells, which act as suppressor cells in oral tolerance in rat EAU (14) . Thus, oral administration of the HLA peptide could ameliorate and prevent uveitis in rats that were immunized with the whole S-Ag, peptide PDSAg or IRBP (8) . Lymphocytes from uveitis patients can proliferate in response to both peptides (8) and therefore we performed a successful therapeutic trial for uveitis patients with oral administration of the HLA peptide B27PD (15) .
The 14mer peptides PDSAg and B27PD share only ®ve identical or similar amino acids in discontinuous order. Both peptides have the same tolerogenic potency; however, the uveitogenicity of PDSAg drastically exceeds that of B27PD. The latter induces only mild disease (average score 0.5) iñ 85% of rats, whereas peptide PDSAg induces severe uveitis (average score~3) in almost 100% of rats after immunization. To elucidate the different properties of pathogenic and tolerogenic epitopes we analyzed C-and N-terminally truncated peptides as well as chimeric variants consisting of amino acids from both peptides. In vitro we investigated the ability of these peptides to stimulate PDSAg-speci®c T cells, the binding to MHC class II molecules was tested by inhibiting the presentation of PDSAg to a PDSAg-speci®c class II-restricted T cell line. In vivo we determined the uveitogenic and tolerogenic potential of variant peptides in Lewis rats.
Methods

Peptides
Variants of peptides PDSAg and B27PD were synthesized that lacked either N-or C-terminal amino acids, or consisted of amino acid sequences of both peptides. Peptide KerS is derived from cytokeratin 5 (amino acids 336±347) and a truncated variant of the arthritogenic peptide Ker333 (16) . All peptides (>80% purity) were purchased from Biotrend (Cologne, Germany). The amino acid sequences (single-letter code) are listed in Table 1 .
Animals
Male and female Lewis rats were bred in our own colony or obtained from Janvier (Le-Genest-St Isle, France) and used for experiments at the age of 6±8 weeks. They had unlimited access to rat chow and water. Animal experiments were approved by the Review Board of the Government of Oberbayern, and conformed to the ARVO Statement on the Use of Animals in Ophthalmic and Vision Research.
Immunization
Groups of three or four rats were immunized s.c. into both hind legs with a total volume of 200 ml emulsion containing 50 mg peptide (PDSAg: 20 mg) and complete Freund's adjuvant, forti®ed to a ®nal concentration of 2.5 mg/ml with Mycobacterium tuberculosis strain H37RA (Difco/Becton Dickinson, Heidelberg, Germany).
Induction of oral tolerance
Groups of three or four rats were fed with peptides (200 mg of peptide in PBS, 3±4 times at 2-day intervals) and uveitis was induced by immunization with 20 mg PDSAg 2 days after the last oral tolerization. All experiments were repeated at least 2 times to con®rm the results.
Grading of uveitis
Clinical examination was performed daily from day 10 postimmunization. For histological grading, eyes were snap frozen in Tissue Tec OCT compound (Paesel and Lorey, Frankfurt/ Main, Germany) in methylbutane, chilled to ±70°C. Cryosections of rat eyes were stained for CD4 with antibody W3/25 (Biozol, Eching, Germany) and the APAAP (alkaline phosphatase±anti-alkaline phosphatase) technique as published previously (8) . Uveitis was graded histologically as described elsewhere (17) . Brie¯y, a score of 0.5 describes the in®ltration of a few cells in the retina and vitreous; the maximum score of 4 describes the total destruction of the retina. Values are given as mean T SE.
Cell cultures
Draining inguinal, popliteal and para-aortal lymph nodes from immunized rats were collected and assayed as described (8) . T cell lines were generated by alternating cycles of antigen stimulation with irradiated thymocytes (10 Gy) as antigenpresenting cells followed by expansion in culture medium supplemented with rat spleen conditioned medium (18) . For proliferation assays, 2 Q 10 4 PDSAg-or KerS-speci®c T cells were cultivated with 2 Q 10 5 irradiated (10 Gy) thymocytes per well as antigen-presenting cells and 10 mg/ml peptide. Cultures were set up in triplicates and proliferation was determined by [ 3 H]thymidine incorporation for the last 12±16 h of a 3-day cell culture. Values are given as mean T SE.
Determination of PDSAg-presenting MHC molecules by antibodies
PDSAg-or KerS-speci®c CD4 + T cell lines were cultured with irradiated thymocytes, the respective antigen peptides, and serial dilutions of MHC class II-speci®c antibodies Ox17 (RT1.D; Becton Dickinson Heidelberg, Germany) and Ox6 (RT1.B; Becton Dickinson) for 3 days. Proliferation was determined as described above.
Competitive inhibition of PDSAg binding to MHC class II by variant peptides
Irradiated (10 Gy) thymocytes (2 Q 10 5 /microwell) from 4-to 6-week-old naive rats were pre-cultured in serum-free medium with increasing concentrations of competitor peptides (dilutions from 2.5 to 75 mM) for 2 h at 37°C before addition of 1.5 mM PDSAg and the PDSAg-speci®c T cell line or KerS and KerS-speci®c T cell line respectively, and were further incubated as described above. MHC-binding was de®ned as reduced proliferation of the T cell line due to inhibition of PDSAg or KerS presentation. In parallel, proliferation of both T cell lines in response to the competitor peptides only was determined.
Results
De®nition of the PDSAg-presenting MHC molecule by antibody inhibition
To de®ne the restriction element for peptide PDSAg and control peptide KerS, antibodies speci®c for RT1.B or RT1.D were added to the cultures of PDSAg-and KerS-speci®c T cell lines. Inhibition of proliferation of the PDSAg-speci®c line was only observed with co-culture of antibody Ox6 (anti RT1.B) ( Fig. 1a ), suggesting a presentation of peptide PDSAg by RT1.B l . Our binding studies with truncated and chimeric peptides are therefore only related to RT1.B binding. A potential presentation of variant peptides by RT1.D cannot be excluded, but could not be detected in our system. Peptide KerS could also be presented by RT1.D, as suggested by the ef®cient inhibition of KerS-speci®c proliferation in co-culture with high concentrations (5 mg/ml) of antibody Ox17. Further dilution of Ox17 resulted in loss of inhibition. RT1.B-speci®c antibody Ox6 was highly inhibitory even at low concentrations such as 0.05 mg/ml. T cell line KerS was therefore regarded as RT1.B-restricted ( Fig. 1b) .
In vitro testing of variant peptides
All peptides were tested for their capacity to induce proliferation of PDSAg-and KerS-speci®c T cell lines, and to compete with peptides PDSAg or KerS for MHC class II presentation, resulting in an inhibition of proliferation of PDSAg-or KerS-speci®c T cells if the peptide itself was not recognized by the T cell line.
Proliferative response of PDSAg-speci®c as well as KerS-speci®c T cell lines and competition assays de®ning the binding of variant peptides to MHC class II were repeated several times. We tested different T cell lines and increasing concentrations of inhibitor peptides, as described in Methods. Since it is impossible to obtain T cell clones in the rat system, we had to use highly speci®c T cell lines. Despite this limitation, we obtained comparable, but slightly variable, results with PDSAg-speci®c ( Fig. 2b and c) and oligoclonal KerS-speci®c T cell lines ( Fig. 2j and l) , and show representative experiments for proliferation assays and MHC binding competition, both from the same PDSAg-or KerS-speci®c cell line. We also tested various KerS-speci®c lines in independent experiments and found similar inhibition patterns, as with the PDSAg-speci®c lines.
In contrast to the PDSAg-speci®c line, the KerS-speci®c cells did not cross-react with any of the tested peptides, they were monospeci®c KerS ( Fig. 2i and k) . PDSAg was the best stimulator of PDSAg-speci®c T cell lines, but some peptides (truncated PDSAg V2±V5, PDSAgV13 and the chimera B-S) also induced proliferation of this T cell line ( Fig. 2a ), indicating that they were presented by RT1.B. However, these peptides stimulated the TCR less ef®ciently than PDSAg itself. Their potency to inhibit the proliferation (40±50%, Fig. 2b ) of the PDSAg-speci®c lines suggests ef®cient MHC-binding and competition for the presentation of PDSAg, although the inhibition of proliferation was lower than with other ef®cient MHC binders, such as the octamer peptides, and B27PD and its variants. This might be due to an overlapping effect of the inhibition of PDSAg presentation and the stimulatory capacity of PDSAg-speci®c T cells by these peptides.
Truncated peptide PDSAgV11 did not ef®ciently stimulate PDSAg-speci®c T cell lines; however, in our assay this peptide was able to compete with PDSAg for MHC class II-binding. No binding of PDSAgV11 to RT1.B was observed in an in vitro binding assay with isolated RT1.B molecules (K. De Graaf, pers. commun.), suggesting that the competition assay is more sensitive.
Peptide B27PD and its N-terminally truncated variants (B27V4±B27V6) bound to MHC class II, but did not stimulate proliferation of PDSAg-speci®c T cell lines ( Fig. 2a and b ). The chimeric peptide B-S consisting of the N-terminal part of B27PD and the C-terminal part of PDSAg was strongly stimulating the proliferation of PDSAg-speci®c T cell lines in vitro ( Fig. 2e and f ). This indicates that the major epitope for a PDSAg-speci®c TCR is located at the C-terminus of PDSAg. With the exception of B-S and Chi1(10), chimeric peptides did not bind to RT1.B in vitro (Fig. 2f ). The octamer peptides PDSAgS, B27PDS, ConsS and ConsT bound strongly to RT1.B, but were not recognized by T cells in vitro and in vivo. Decreased proliferation caused by competitor peptides was not due to the toxicity of the peptides itself as demonstrated by co-incubation of high concentrations (75 mM) of variant peptides with PDSAg-speci®c T cells and PDSAg (data not shown). Despite the important role of the C-terminal amino acids of PDSAg, some truncated peptides were even more effective than their elongated form with respect to MHCbinding [PDSAgV11 versus PDSAgV12 (Fig. 2b) , Chi1(10) versus Chi1(11) ( Fig. 2f) ].
The pattern of inhibition observed with truncated peptides and the KerS-speci®c line ( Fig. 2j and l) was similar to that observed with the PDSAg-speci®c cells. The inhibition of proliferation of the KerS-speci®c line by N-and C-terminally truncated PDSAg-derived peptides was weaker than the inhibition of the PDSAg line, probably due to the fact that the KerS-speci®c T cells were more vigorously proliferating to KerS (SI = 82) than the PDSAg-speci®c cells to PDSAg (SI = 43). The assays were done at different time points with T cell lines obtained from rats of a different source and, in part, with different batches of peptides, which might explain some variations.
The 14mer peptide B27PD was less ef®cient in competing for MHC-binding with KerS than with PDSAg; however, N-terminal truncated peptides B27V4±V6 (Fig. 2j ) and the chimera with the C-terminus of B27PD, S-B (Fig. 2l ), were highly competitive and ef®ciently inhibited (75%) the proliferation of KerS-speci®c T cells. This points to an important role of the C-terminal sequence of B27PD in binding to the MHC groove and competing for KerS. Peptide B-S, which was able to stimulate proliferation of PDSAg-speci®c T cells and thus ef®cient binding to RT1.B, did not compete for KerS-binding. The highly ef®cient blockade of the MHC groove by octamer peptides PDSAgS, B27PDS, ConsS and ConsT was also not observed with KerS-speci®c lines.
In vivo testing of variant peptides
In several independent experiments the peptides were tested for their uveitogenicity as well as their capacity to induce oral tolerance to PDSAg-mediated disease. Because of interexperimental variants in disease activity, the effectivity of oral tolerance induction was calculated for each experiment as relative intensity (percent severity) of uveitis in relation to the respective mock control (de®ned as 100%). Only variants of PDSAg with N-terminal truncations of up to 3 amino acids (PDSAgV2±V4) or truncation of one C-terminal amino acid (PDSAgV13) retained the ability to induce uveitis and oral tolerance ( Fig. 2c and d) . Truncated peptide PDSAgV11 induced severe uveitis, but with a very low incidence (only 10% of immunized rats developed disease). Peptide B27PD and its N-terminally truncated variants induced oral tolerance; however, they were not or only weakly uveitogenic (B27PD and B27V5). Two chimeric peptides, S-1-B (N-terminus from PDSAg and C-terminus from B27PD) and Chi 2(10) (with the C-terminus similar to B27PD) did not induce uveitis, but were weakly tolerogenic ( Fig. 2g and h) . Peptides S-B and B-S were not effective in vivo, although B-S induced proliferation of T cells in vitro. The differences of effector T cell recognition versus tolerogenicity underline our previous data of gd T cells as effector cells in oral tolerance: they are CD4 ± and thus believed to recognize peptides in a different way than the effector cells, probably not presented by MHC class II (14) . The four octamer peptides, PDSAgS, B27PDS, ConsS and ConsT, were not recognized by T cells in vivo, which is in concordance with their inability to stimulate T cell lines in vitro.
Potential MHC-binding motifs
We wanted to de®ne the binding motifs of the peptides to RT1.B l (Fig. 3) according to the anchor positions described by Reizis et al. (19) . Amino acids at positions 4 (no negative charge) and 9 (negative charge preferred) are suggested to be the most important anchors, therefore the sequences from amino acids 5 to 13 of the 14mer peptides PDSAg and B27PD (LTSSEVATE and DLSSWTAAD respectively) should represent the optimal binding motif ( Fig. 3a) . This region is expressed in all truncated forms of PDSAg that still showed strong immunological activity or bound to MHC (PDSAgV2± V5, PDSAgV13 and B27V4±V5). Peptide PDSAg V5V13, which only consists of this core motif, bound to RT1.B l , as shown by competition for PDSAg-binding in Fig. 2(b) , but was not properly recognized by T cells (Fig. 2a ). Peptide PDSAgV11 bound to RT1.B, although it did not have the proposed anchors at positions 4 and 9 (Fig. 2b) . A potential motif in this peptide spans the ®rst 9 amino acids of PDSAg (FLGELTSSE) and includes a negatively charged amino acid at position 9, but has an unfavored acidic side-chain at position 4 (Fig. 3b ). Further suggested binding motifs of PDSAg covering amino acids 2±10 (LGELTSSEV) or 3±11 (GELTSSEVA) have a more favorable residue at position 4 (leucine or threonine), but lack the negative charge at position 9 (Fig. 3b) .
Possible alignments are shown for those chimeric peptides which bind to MHC in Fig. 3(c) . T cells recognized some of them as well. Although all peptides have respective binding motifs, some [S-B, S-1-B and Chi2(10)] did not bind well enough to ef®ciently compete with PDSAg-binding to RT1.B. Peptide Chi2(10) with the least number of MHC anchors (Fig. 3c ) did not elicit proliferation of PDSAg-speci®c T cells in vitro, but was pathogenic (uveitis score 3) in one of 10 immunized rats (Fig. 2b) . Chi2(10) and S-1-B, but not S-B, were weakly tolerogenic after oral administration (Fig. 2h) . The core motif of peptide B-S differs by only 2 amino acids from that of PDSAg (DL versus LT). Although it induced proliferation of PDSAg-lines in vitro, it was inef®cient in vivo with respect to uveitogenicity as well as oral tolerogenicity. Whereas both peptides, PDSAg and B27PD, bound well to RT1.B l , the chimeric peptide S-B, consisting of the N-terminus of PDSAg and the C-terminus of B27PD, did not compete with PDSAg for RT1.B-binding despite its potential anchor positions 1, 3, 4, 6 and 9 (Fig. 3b) .
Peptide KerS has only three favored amino acids at anchor positions 1, 5 and 9 (Fig. 3a) .
Discussion
The goal of this study was to determine the immunological differences between a peptide derived from retinal S-Ag (PDSAg, highly pathogenic and tolerogenic in the rat model of EAU) and the cross-reactive HLA peptide B27PD, which is highly tolerogenic but poorly uveitogenic. Here, we wanted to compare the two given amino acid sequences, i.e. those of peptides PDSAg and B27PD, with each other and therefore refrained from the conventional alanine substitutions. Instead we tested truncations as well as combinations of amino acids from the sequences of both peptides. So far, we only have information about the anchor positions for binding to Lewis rat MHC class II molecule RT1.B l , but not about the contact residues of the TCR. To distinguish between MHC-binding and T cell recognition we investigated whether these peptides compete with PDSAg-binding by subsequently testing the proliferation of PDSAg-speci®c T cell lines as well as the response of the T cell lines to the competitor peptides alone. Furthermore, we looked for the ability of the peptides to induce uveitis and/or oral tolerance in vivo.
The binding competition assay revealed a minimal nonamer motif for RT1.B l according to the de®nition of Reizis et al. (18) represented by peptide V5V13 of PDSAg (LTSSEVATE). This peptide was suf®cient to inhibit PDSAg binding, but was still not able to stimulate the proliferation of a PDSAg-speci®c T cell line. This argues for the importance of amino acids¯anking the core motif, recently described to be necessary for the interaction with the TCR (20) . Truncating peptide PDSAg by 1 amino acid N-terminally (PDSAgV13) or C-terminally (PDSAgV2) resulted in peptides with reduced capability to stimulate PDSAg-speci®c T cell lines. Whereas truncation of up to 4 N-terminal amino acids (PDSAgV3±V5) did not completely abrogate T cell proliferation, the peptide lacking 2 C-terminal amino acids (PDSAgV12) had lost its immunological activity, suggesting that the epitope for TCR binding must be located at the C-terminus of peptide PDSAg. This was con®rmed by the chimeric peptide B-S, which is composed of the N-terminal part of peptide B27PD and the C-terminal part of PDSAg. B-S stimulated PDSAg-speci®c T cells, but less ef®ciently than PDSAg itself. However, it did not induce uveitis in vivo suggesting that it is either not binding well enough to MHC class II to compete with other peptides in vivo, or it is unable to activate naive, potentially pathogenic T cells due to insuf®cient avidity of the TCR. For different allelic MHC class II variants it has been found that encephalitogenicity in rat EAE correlates with the af®nity of the myelin basic protein peptides for the restricting MHC class II molecules (21) .
On the other hand, it has been reported for the mouse model of EAE that peptides binding to MHC with high af®nity were not pathogenic (22) , as well as pathogenic peptides that had only a very low af®nity to MHC class II molecules (23) . For most, but not all, of our tested peptides, we observed a correlation between binding to MHC class II and stimulation of T cell lines in vitro, and uveitogenicity and oral tolerogenicity in vivo. Except for peptide B-S, we found some other peptides with distinct functions in vitro and in vivo: the chimeric peptide Chi1(10), composed of single amino acids of both founder peptides and including a stretch of 4 amino acids that corresponds to the sequence of B27PD, showed good binding to MHC class II (RT1.B l ) without being recognized by PDSAg-speci®c T cells. In contrast, peptide Chi2(10), inducing uveitis in one of 10 immunized rats, was unable to stimulate T cell lines in vitro. This peptide lacks postulated favored amino acids at the most important anchor positions 4 and 9. However, positions 2, 5 and 8, which are thought to be recognized by the TCR, are identical to those of peptide PDSAg [ Fig. 3c (Chi2(10)-a) ]. This motif has tryptophan (W) at position 4, where, according to Reizis et al. (18) , phenylalanine (F) is preferred, indicating that tryptophan might function as an anchor as well. The lack of an aliphatic or negatively charged anchor at position 9 might explain the weak MHC-binding, resulting in very low pathogenicity, i.e. in only one of 10 immunized rats. The latter might be due to a rare TCR with strong avidity that could compensate for the weak MHCbinding of the antigen peptide. Nevertheless, we could not exclude the presentation of peptide Chi2(10) by RT1.D, for which the binding motifs are still unknown. Chi2(10) might stimulate a non-dominant T cell response restricted for RT1.D. Surprisingly, we could observe an improvement of function of some peptides by further truncation of single amino acids [Chi1 (11) versus Chi1(10) and PDSAgV12 versus PDSAgV11], although we expected that removal of amino acids would rather destroy than rescue epitopes. We suspect that¯anking amino acids might stabilize the elongated structure of the respective motifs and enable the peptides to ®t better into the groove of RT1.B. Chi1 (10) , in contrast to Chi1(11), bound to MHC, but was not recognized by T cells in vitro nor in vivo, indicating that it has respective MHC-binding residues without the suitable amino acids recognized by the TCR. Peptides PDSAgV12 and PDSAgV11 showed even more striking differences. The 12mer PDSAgV12 was poorly MHC-binding, and consequently did not stimulate T cells in vivo and in vitro. The 11mer PDSAgV11 was moderately binding to RT1.B, therefore weakly stimulating PDSAg-speci®c T cells, and poorly uveitogenic in vivo. Only 10% of immunized rats developed uveitis, however, it was a severe disease, indicating an all-ornothing-phenomenon: when a pathogenic immune response was initiated, it was highly effective. T cells recognizing PDSAgV11 might as well utilize a different TCR than those activated by PDSAg. Primary in vitro responses of lymph node cells from rats immunized with PDSAgV11 frequently exhibit a heteroclitic proliferative response to PDSAg, whereas further re-stimulation in vitro with PDSAgV11 selected for exclusive PDSAgV11 speci®city (data not shown).
Binding of variant peptides to Lewis rat MHC class II RT1.B l was determined by in vivo competition for the binding groove for either peptide PDSAg or a control peptide, KerS, and the inhibition of proliferation of respective T cell lines. This system is very sensitive, but also affected by variables like the fact that T cell lines are inhomogeneous and composed of variable subpopulations with different TCR avidities which might recognize different contact residues on a presented peptide epitope (24) . Furthermore, proliferative responses of some T cells recognizing peptide presented by RT1.D l might quench the effect of blocking RT1.B. Several factors can in¯uence the binding of peptides to MHC class II in vitro: the availability of free MHC grooves, competition with other peptides present in the culture medium, the pH of the culture, which can affect the hydrogenation and charge of the peptide's amino acid sidechains, and ®nally further proteolytic degradation of the peptides. With respect to TCR-binding, little is known about the factors that could modify T cell recognition. Nevertheless, our experiments with two different T cell lines of completely different peptide speci®cities did not reveal contradictory results.
Our ®ndings question the general opinion that peptides of any length exceeding the minimal binding motif can be used to detect naturally occurring T cell responses. Long peptides including more than one MHC-binding motif, several T cell epitopes or even epitopes with immunoregulatory properties are unpredictable in their function, which was previously shown for a region from the sequence of HLA-B27 (amino acids 60±84). A peptide corresponding to the N-terminal part of this region (amino acids 60±72) can induce proliferation of peripheral blood lymphocytes from patients with ankylosing spondylitis (25) and is arthritogenic in Lewis rats (27) . The C-terminal part includes an immunoregulatory sequence (26) which can positively in¯uence CD4 + -mediated experimental autoimmune diseases such as EAU and has a negative effect on oral tolerance induction (28) .
In conclusion, we could not clearly de®ne MHC-binding motifs or amino acids responsible for recognition by uveitogenic ab TCR + cells. Amino acids¯anking the core epitope or certain combinations of amino acids can obviously in¯uence the structure of a peptide in an unpredictable way (19, 29) , and therefore inhibit or favor MHC presentation and/or recognition by T cells. With respect to pathogenicity or tolerogenicity, none of the variant peptides had a higher immunological activity than the original 14mer peptides PDSAg or B27PD. For oral tolerance induction, which is based on gd T cell activation in our rat model, no prediction for suitable peptide sequences could be made, since neither the presenting molecule nor the way of presentation of peptide antigens to these gd TCR is known so far. Furthermore, our data point out the differences between in vitro and in vivo responses of T cells. In vitro, speci®c T cell lines can still be able to react to peptides that highly differ from their original antigen, whereas in vivo such putative cross-reactive peptides are unable to induce disease or tolerance. In the human situation, where only in vitro assays are available to test potentially pathogenic or tolerogenic epitopes, the results from cell cultures with T cell clones might be misleading and not representative of the in vivo situation.
